EU to Review Rare Disease Drugs Market Exclusivity  

Oleh:

Sheridan, Cormac

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 22 no. 9 (Sep. 2004), page 1061.
Topik: DRUG; disease drug market

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.1 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Biotech companies that base their business strategy on orphan drug development are branching themselves for a european commission (EC report on orphan drug pricing). EC officials are finalizing a study this month on the relationship between profitability and market exclusivity provisions, focused on the first eleven approved orphan drugs allowed in the european union. Industry observers fear that by 2005, the EC will tighten the legislation by reducing market exclusivity. A 10 year market exclusivity remains the main carrot to entice companies to develop new drugs agains rare disease .....

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali